Abstract
A series of novel aryloxazolidine-2,4-diones was synthesized. A structure-activity relationship study of these compounds led to the identification of potent, orally active PPAR dual alpha/gamma agonists. Based on the results of efficacy studies in the db/db mice model of type 2 diabetes and the desired pharmacokinetic parameters, compound 12 was selected for further profiling.
MeSH terms
-
Administration, Oral
-
Hypoglycemic Agents / chemistry
-
Hypoglycemic Agents / pharmacokinetics
-
Hypoglycemic Agents / pharmacology*
-
Oxazoles / chemistry
-
Oxazoles / pharmacokinetics
-
Oxazoles / pharmacology*
-
Receptors, Cytoplasmic and Nuclear / agonists*
-
Structure-Activity Relationship
-
Transcription Factors / agonists*
Substances
-
Hypoglycemic Agents
-
Oxazoles
-
Receptors, Cytoplasmic and Nuclear
-
Transcription Factors